O. Lindqvist, G. Lundquist, A. Dickman, J. Bükki, U. Lunder et al., Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion

N. Sykes, The pathogenesis of constipation, J Support Oncol, vol.4, issue.5, pp.213-221, 2006.

S. Bader, K. Jaroslawski, H. Blum, and G. Becker, Opioid-Induced Constipation in Advanced Illness: Safety and Efficacy of Methylnaltrexone Bromide, Clin Med Insights Oncol, vol.5, pp.201-212, 2011.

M. Herbert and P. Holzer, Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients???Current status and future options, Clinical Nutrition, vol.27, issue.1, pp.25-41, 2008.
DOI : 10.1016/j.clnu.2007.08.001

P. Ducrotté, Constipation et traitements par les opioïdes Physiopathologie et prise en charge. Douleurs : Evaluation -Diagnostic -Traitement, pp.171-178, 2009.

T. Piche, Recommandations pour la pratique clinique dans la prise en charge et le traitement de la constipation chronique de l???adulte, Gastroent??rologie Clinique et Biologique, vol.31, issue.2, pp.125-135, 2007.
DOI : 10.1016/S0399-8320(07)89342-0

A. Porter, D. Wattchow, A. Hunter, and M. Costa, Abnormalities of nerve fibers in the circular muscle of patients with slow transit constipation, International Journal of Colorectal Disease, vol.13, issue.5-6, pp.5-6208, 1998.
DOI : 10.1007/s003840050163

D. Burkitt, A. Walker, and N. Painter, EFFECT OF DIETARY FIBRE ON STOOLS AND TRANSIT-TIMES, AND ITS ROLE IN THE CAUSATION OF DISEASE, The Lancet, vol.300, issue.7792, pp.1408-1420, 1972.
DOI : 10.1016/S0140-6736(72)92974-1

G. Mccrea, Pathophysiology of constipation in the older adult, World Journal of Gastroenterology, vol.14, issue.17, p.2631, 2008.
DOI : 10.3748/wjg.14.2631

M. Davis, Cancer constipation: are opioids really the culprit? Support Care Cancer, pp.427-436, 2008.

D. Ponti, F. Giaroni, C. Cosentino, M. Lecchini, S. Frigo et al., Adrenergic mechanisms in the control of gastrointestinal motility: From basic science to clinical applications, Pharmacology & Therapeutics, vol.69, issue.1, pp.59-78, 1996.
DOI : 10.1016/0163-7258(95)02031-4

M. Sobczak, M. Sa?aga, M. Storr, and J. Fichna, Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives, Journal of Gastroenterology, vol.70, issue.2, 2013.
DOI : 10.1007/s00535-013-0753-x

B. Rachinger-adam, P. Conzen, and S. Azad, Pharmacology of peripheral opioid receptors, Current Opinion in Anaesthesiology, vol.24, issue.4, pp.408-421, 2011.
DOI : 10.1097/ACO.0b013e32834873e5

D. Dehaven-hudkins, R. Dehaven, P. Little, and L. Techner, The involvement of the ??-opioid receptor in gastrointestinal pathophysiology: Therapeutic opportunities for antagonism at this receptor, Pharmacology & Therapeutics, vol.117, issue.1, pp.162-87, 2008.
DOI : 10.1016/j.pharmthera.2007.09.007

K. Fakata, A. Tuteja, and . A. Lipman, Opioid bowel dysfunction in acute and chronic nonmalignant pain, Handbook of opioid bowel syndrome, pp.101-120, 2007.

S. Panchal, P. Muller-schwefe, and J. Wurzelmann, Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden, International Journal of Clinical Practice, vol.10, issue.Suppl. 1, pp.1181-1188, 2007.
DOI : 10.1111/j.1742-1241.2007.01415.x

J. Wood and J. Galligan, Function of opioids in the enteric nervous system, Neurogastroenterology and Motility, vol.247, issue.s2, pp.17-28, 2004.
DOI : 10.1016/0014-2999(87)90409-2

M. Fallon and G. Hanks, Short reports: Morphine, constipation and performance status in advanced cancer patients, Palliative Medicine, vol.13, issue.2, pp.159-60, 1999.
DOI : 10.1191/026921699677653615

N. Sykes, Opioid bowel dysfunction in palliative care Handbook of opioid bowel syndrome, 1 st ed, pp.69-100, 2007.

L. Bohn and K. Raehal, Opioid receptor signaling: relevance for gastrointestinal therapy, Current Opinion in Pharmacology, vol.6, issue.6, pp.559-63, 2006.
DOI : 10.1016/j.coph.2006.06.007

E. Kalso, J. Edwards, R. Moore, and H. Mcquay, Opioids in chronic non-cancer pain: systematic review of efficacy and safety, Pain, vol.112, issue.3, pp.372-80, 2004.
DOI : 10.1016/j.pain.2004.09.019

. Société-française-d, Accompagnement et de Soins Palliatifs Recommandations pour la prévention et le traitement de la constipation induite par les opioïdes chez le patient relevant de soins palliatifs, Méd. Palliat, vol.8, pp.5-33, 2009.

P. Klepstad, S. Kaasa, A. Jystad, B. Hval, and P. Borchgrevink, Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial, Pain, vol.101, issue.1, pp.193-201, 2003.
DOI : 10.1016/S0304-3959(02)00328-7

A. Vainio and A. Auvinen, Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group, J Pain Symptom Manage, 1996.

M. Pappagallo, Incidence, Prevalence, and Management of Opioid Bowel Dysfunction, The American Journal of Surgery, vol.182, issue.5, pp.11-18, 2001.
DOI : 10.1016/S0002-9610(01)00782-6

A. Olesen and A. Drewes, Validated tools for evaluating opioid-induced bowel dysfunction, Advances in Therapy, vol.12, issue.suppl.2, pp.279-94
DOI : 10.1007/s12325-011-0006-4

E. Klaschik, F. Nauck, and C. Ostgathe, Constipation--modern laxative therapy. Support Care Cancer, pp.679-85, 2003.

J. Foss, A Review of the Potential Role of Methylnaltrexone in Opioid Bowel Dysfunction, The American Journal of Surgery, vol.182, issue.5, pp.19-26, 2001.
DOI : 10.1016/S0002-9610(01)00783-8

G. Kyle, Constipation and palliative care ??? where are we now?, International Journal of Palliative Nursing, vol.13, issue.1, 2007.
DOI : 10.12968/ijpn.2007.13.1.22776

J. Thomas, Cancer-related constipation, Current Oncology Reports, vol.131, issue.16S, pp.278-84, 2007.
DOI : 10.1007/s11912-007-0034-z

B. Hess, M. Bernardi, and H. Klotz, Attitude of Swiss physicians towards opioid-induced constipation: A national survey, European Journal of Internal Medicine, vol.22, issue.5, pp.527-558, 2011.
DOI : 10.1016/j.ejim.2011.02.014

A. Connell, C. Hilton, G. Irvine, J. Lennard-jones, and J. Misiewicz, Variation of bowel habit in two population samples., BMJ, vol.2, issue.5470, pp.11-13, 1966.
DOI : 10.1136/bmj.2.5470.1095

M. Herz, E. Kahan, S. Zalevski, R. Aframian, D. Kuznitz et al., Constipation: a different entity for patients and doctors. Fam Pract, pp.156-165, 1996.

K. Clark and D. Currow, Constipation in Palliative Care: What Do We Use as Definitions and Outcome Measures?, Journal of Pain and Symptom Management, vol.45, issue.4, pp.753-62
DOI : 10.1016/j.jpainsymman.2012.03.016

M. Camilleri, M. Rothman, K. Ho, and M. Etropolski, Validation of a Bowel Function Diary for Assessing Opioid-Induced Constipation, The American Journal of Gastroenterology, vol.105, issue.3, pp.497-506, 2011.
DOI : 10.1038/ajg.2010.431

C. Regnard, J. Hockley, and J. Hockley, A Guide to Symptom Relief in Palliative Care, 2004.

K. Clark, L. Lam, M. Agar, R. Chye, and D. Currow, The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis, Palliative Medicine, vol.24, issue.4, pp.410-418, 2010.
DOI : 10.1177/0269216310363649

W. Rhondali, L. Nguyen, L. Palmer, D. Kang, D. Hui et al., Self-Reported Constipation in Patients With Advanced Cancer: A Preliminary Report, Journal of Pain and Symptom Management, vol.45, issue.1, pp.23-32, 2013.
DOI : 10.1016/j.jpainsymman.2012.01.009

A. Noguera, C. Centeno, S. Librada, and M. Nabal, Screening for Constipation in Palliative Care Patients, Journal of Palliative Medicine, vol.12, issue.10, pp.915-935, 2009.
DOI : 10.1089/jpm.2009.0054

C. Knowles, S. Scott, P. Legg, M. Allison, and P. Lunniss, Level of classification performance of KESS (symptom scoring system for constipation)

A. Rentz, R. Yu, S. Müller-lissner, and P. Leyendecker, Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation, Journal of Medical Economics, vol.12, issue.4, pp.371-83, 2009.
DOI : 10.3111/13696990903430481

N. Cherny, C. Ripamonti, J. Pereira, C. Davis, M. Fallon et al., Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report, Journal of Clinical Oncology, vol.19, issue.9, pp.2542-54, 2001.
DOI : 10.1200/JCO.2001.19.9.2542

R. Choung, G. Locke, C. Schleck, A. Zinsmeister, and N. Talley, T1023 Epidemiology of Opioid Bowel Dysfunction and Narcotic Bowel Syndrome in the Community, Gastroenterology, vol.134, issue.4, 2008.
DOI : 10.1016/S0016-5085(08)62184-8

T. Bell, S. Panchal, C. Miaskowski, S. Bolge, T. Milanova et al., The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1), Pain Medicine, vol.10, issue.1, pp.35-42, 2009.
DOI : 10.1111/j.1526-4637.2008.00495.x

A. Tuteja, J. Biskupiak, G. Stoddard, and A. Lipman, Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain, Neurogastroenterology & Motility, vol.101, issue.4, 2010.
DOI : 10.1111/j.1365-2982.2009.01458.x

N. Sykes, The relationship between opioid use and laxative use in terminally ill cancer patients, Palliative Medicine, vol.12, issue.5
DOI : 10.1191/026921698674125048

F. Wigzell, The Health of Nonagenarians, Gerontologia Clinica, vol.11, issue.3, pp.137-181, 1969.
DOI : 10.1159/000245227

R. Moore and H. Mcquay, Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids, Arthritis Research & Therapy, vol.7, issue.5, pp.1046-1051, 2005.
DOI : 10.1186/ar1782

A. Furlan, J. Sandoval, A. Mailis-gagnon, and E. Tunks, Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects, Canadian Medical Association Journal, vol.174, issue.11, pp.1589-94, 2006.
DOI : 10.1503/cmaj.051528

E. Eisenberg, E. Mcnicol, and D. Carr, Opioids for neuropathic pain, Cochrane Database of Systematic Reviews, vol.293, issue.24, 1996.
DOI : 10.1002/14651858.CD006146

K. Clark, L. Lam, M. Agar, R. Chye, and D. Currow, The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis, Palliative Medicine, vol.24, issue.4, pp.410-418, 2010.
DOI : 10.1177/0269216310363649

A. Karci, Evaluation of Quality in Patient-Controlled Analgesia Provided by an Acute Pain Service, European Surgical Research, vol.35, issue.4, pp.363-71, 2003.
DOI : 10.1159/000070608

P. Hawley and J. Byeon, A Comparison of Sennosides-Based Bowel Protocols with and without Docusate in Hospitalized Patients with Cancer, Journal of Palliative Medicine, vol.11, issue.4, pp.575-81, 2008.
DOI : 10.1089/jpm.2007.0178

M. Herbert and P. Holzer, Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients???Current status and future options, Clinical Nutrition, vol.27, issue.1, pp.25-41, 2008.
DOI : 10.1016/j.clnu.2007.08.001

A. Brenner, D. Schoenfeld, and P. , Sa1150 Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis, Gastroenterology, vol.144, issue.5, 2013.
DOI : 10.1016/S0016-5085(13)60756-8

J. Fichna, K. Gach, R. Perlikowska, A. Cravezic, J. Bonnet et al., Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract, Regulatory Peptides, vol.162, issue.1-3
DOI : 10.1016/j.regpep.2010.01.001

M. Tonini, D. Ponti, F. , D. Nucci, A. Crema et al., Review article: cardiac adverse effects of gastrointestinal prokinetics, Alimentary Pharmacology and Therapeutics, vol.13, issue.12, pp.1585-1591, 1999.
DOI : 10.1016/S0196-9781(96)00333-6

A. European-medicine, European Public Assessment Report of RELISTOR, last updated, 2013.

D. Lin, C. Wang, L. Qin, X. Xie, J. Wang et al., Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. Drug Dev Ind Pharm, 2013.

A. Thomas and C. Yuan, Methylnaltrexone : investigations in treating opioid bowel dysfunction Handbook of opioid bowel syndrome, 1 st ed, pp.197-221, 2007.

Y. Rotshteyn, T. Boyd, and C. Yuan, Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration, Expert Opinion on Drug Metabolism & Toxicology, vol.28, issue.7, pp.227-262, 2011.
DOI : 10.1124/dmd.110.032169

A. Kotake, S. Kuwahara, E. Burton, C. Mccoy, and L. Goldberg, Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans, Xenobiotica, vol.32, issue.11, 1989.
DOI : 10.1016/0028-3908(85)90072-3

. Méthylnaltrexone-relistor, Constipation sous morphinique : guère plus efficace qu'un placebo, Rev Prescrire, vol.29, issue.305, pp.172-173, 2009.

R. Morphy, C. Kay, and Z. Rankovic, From magic bullets to designed multiple ligands, Drug Discovery Today, vol.9, issue.15, pp.641-651, 2004.
DOI : 10.1016/S1359-6446(04)03163-0

R. Portenoy, J. Thomas, M. Boatwright, M. Tran, D. Galasso et al., Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study, Journal of Pain and Symptom Management, vol.35, issue.5, pp.458-68, 2008.
DOI : 10.1016/j.jpainsymman.2007.12.005

J. Thomas, A. Lipman, N. Slatkin, G. Wilson, M. Moehl et al., A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI), ASCO Annual Meeting Proceedings, p.8003, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.lba8003

J. Thomas, S. Karver, G. Cooney, B. Chamberlain, C. Watt et al., Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness, New England Journal of Medicine, vol.358, issue.22, pp.2332-2375, 2008.
DOI : 10.1056/NEJMoa0707377

L. Webster, E. Michna, A. Khan, R. Israel, A. Manley et al., The long-term safety of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain, The Journal of Pain, vol.12, issue.4, pp.70-70, 2011.
DOI : 10.1016/j.jpain.2011.02.285

B. Candy, L. Jones, M. Goodman, R. Drake, and A. Tookman, Laxatives or methylnaltrexone for the management of constipation in palliative care patients, Cochrane Database Syst Rev, issue.1, p.3448, 2011.

R. Israel, J. Thomas, S. Iyer, W. Wang, and N. Stambler, 1121 POSTER The effect of methylnaltrexone on global clinical impression of change (GCIC) in the bowel status of cancer patients with opioid-induced constipation, European Journal of Cancer Supplements, vol.5, issue.4, p.148, 2007.
DOI : 10.1016/S1359-6349(07)70640-7

R. Rauck, J. Peppin, R. Israel, J. Carpenito, J. Cohn et al., 943a Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Noncancer Pain, Gastroenterology, vol.142, issue.5, pp.160-160, 2012.
DOI : 10.1016/S0016-5085(12)60606-4

B. Wong, A. Rao, M. Camilleri, N. Manabe, S. Mckinzie et al., The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health, Alimentary Pharmacology & Therapeutics, vol.61, issue.Suppl. 2, 2010.
DOI : 10.1111/j.1365-2036.2010.04422.x

R. Twycross, N. Sykes, M. Mihalyo, and A. Wilcock, Stimulant Laxatives and Opioid-Induced Constipation, Journal of Pain and Symptom Management, vol.43, issue.2, pp.306-319, 2012.
DOI : 10.1016/j.jpainsymman.2011.12.002

R. Blonsky, E. Michna, S. Schulman, E. Tzanis, A. Manley et al., Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain, The Journal of Pain, vol.10, issue.4, p.52, 2009.
DOI : 10.1016/j.jpain.2009.01.277

C. Agency, . Drug, . Technology, and . Health, Common Drug Review, Methylnaltrexone [serial online Available from: URL: <http://www.cadth.ca/media, 2009.

M. Iskedjian, S. Iyer, L. Librach, S. Wang, M. Farah et al., Methylnaltrexone in the Treatment of??Opioid-Induced Constipation in Cancer Patients Receiving Palliative Care: Willingness-to-Pay and Cost-Benefit Analysis, Journal of Pain and Symptom Management, vol.41, issue.1, 2009.
DOI : 10.1016/j.jpainsymman.2010.04.012

A. Farmer, F. E. Aziz, and Q. , Opioids and the Gastrointestinal Tract - A Case of Narcotic Bowel Syndrome and Literature Review, Journal of Neurogastroenterology and Motility, vol.19, issue.1, 2013.
DOI : 10.5056/jnm.2013.19.1.94

D. Grunkemeier, J. Cassara, C. Dalton, and D. Drossman, The Narcotic Bowel Syndrome: Clinical Features, Pathophysiology, and Management, Clinical Gastroenterology and Hepatology, vol.5, issue.10, pp.1126-1139, 2007.
DOI : 10.1016/j.cgh.2007.06.013

J. Pellat, H. Hodaj, J. Alibeu, J. Payen, and C. Jacquot, Hyperalgésie postopératoire. Douleurs, Feb, vol.7, issue.1, pp.11-17, 2006.

R. Choung, G. Locke, A. Zinsmeister, C. Schleck, and N. Talley, Opioid Bowel Dysfunction and Narcotic Bowel Syndrome: A Population-Based Study, The American Journal of Gastroenterology, vol.47, issue.5, pp.1199-204, 2009.
DOI : 10.1016/S0885-3924(99)00085-8

A. Tuteja, J. Biskupiak, G. Stoddard, and A. Lipman, Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain, Neurogastroenterology & Motility, vol.101, issue.4, pp.424-430, 2010.
DOI : 10.1111/j.1365-2982.2009.01458.x

P. Manickam and A. Saad, Narcotic Bowel Syndrome: Is It More Common Than Before?, Journal of Neurogastroenterology and Motility, vol.19, issue.2, p.273
DOI : 10.5056/jnm.2013.19.2.273

S. Je, M. Mcphee, and G. Nj, Narcotic Bowel Syndrome Treated with ClonidineResolution of Abdominal Pain and Intestinal Pseudo-Obstruction

V. Wong, G. Sobala, and M. Losowsky, A case of narcotic bowel syndrome successfully treated with clonidine., Postgraduate Medical Journal, vol.70, issue.820, pp.138-178, 1994.
DOI : 10.1136/pgmj.70.820.138

D. Drossman, C. Morris, H. Edwards, C. Wrennall, S. Weinland et al., Diagnosis, Characterization, and 3-Month Outcome After Detoxification of 39 Patients With Narcotic Bowel Syndrome, The American Journal of Gastroenterology, vol.9, issue.9, pp.1426-1466, 2012.
DOI : 10.1038/ajg.2009.341

P. Gibson and G. Morrison, Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study, Internal Medicine Journal, vol.358, issue.1, pp.907-919, 2012.
DOI : 10.1111/j.1445-5994.2012.02726.x

L. Weinstock and A. Chang, Methylnaltrexone for Treatment of Acute Colonic Pseudo-obstruction, Journal of Clinical Gastroenterology, vol.45, issue.10, pp.883-887, 2011.
DOI : 10.1097/MCG.0b013e31821100ab

C. Yu, H. Chun, N. Stambler, J. Carpenito, S. Schulman et al., Safety and Efficacy of Methylnaltrexone in Shortening the Duration of Postoperative Ileus Following Segmental Colectomy: Results of Two Randomized, Placebo-Controlled Phase 3 Trials, Diseases of the Colon & Rectum, vol.54, issue.5, pp.570-578, 2011.
DOI : 10.1007/DCR.0b013e3182092bde

M. Herbert and P. Holzer, Standardized concept for the treatment of gastrointestinal 66

S. Sawh, I. Selvaraj, A. Danga, A. Cotton, J. Moss et al., Use of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Critical Care Patients, Mayo Clinic Proceedings, vol.87, issue.3, pp.255-264, 2012.
DOI : 10.1016/j.mayocp.2011.11.014

L. Garten, P. Degenhardt, and C. Bührer, Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone, Journal of Pediatric Surgery, vol.46, issue.3, pp.13-15, 2011.
DOI : 10.1016/j.jpedsurg.2010.10.015

L. Garten and C. Bührer, Reversal of morphine-induced urinary retention after methylnaltrexone, Archives of Disease in Childhood - Fetal and Neonatal Edition, vol.97, issue.2, pp.151-153, 2012.
DOI : 10.1136/archdischild-2011-300213

K. Kissling, L. Mohassel, and J. Heintz, Methylnaltrexone for Opioid-Induced Constipation in a Pediatric Oncology Patient, Journal of Pain and Symptom Management, vol.44, issue.1, pp.1-3
DOI : 10.1016/j.jpainsymman.2012.04.001

A. Rodrigues, C. Wong, A. Mattiussi, S. Alexander, E. Lau et al., Methylnaltrexone for Opioid-Induced Constipation in Pediatric Oncology Patients. Pediatr Blood Cancer, 2013.

J. Lee and J. Mooney, Methylnaltrexone in Treatment of Opioid-induced Constipation in a Pediatric Patient, The Clinical Journal oF Pain, vol.28, issue.4, pp.338-379
DOI : 10.1097/AJP.0b013e31822ad94c

P. Gøtzsche, Efficacité et effets indésirables des produits de santé : données confidentielles ou d'intérêt public ?. Rev Presc. [serial online, 2013.

Y. Loke, D. Price, and A. Herxheimer, Appendix 6b. Including adverse effects, Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [serial online, 2006.

C. Adam, M. Freeman, and K. Frederiksen, Salix and Progenics announce FDA advisory committee to review Relistor sNDA for opioid induced constipation in patients with chronic pain Progenic's Pharmaceutical News [serial online Available from: URL:< http://files.shareholder.com, pp.321-597, 2013.

A. Langlois, L. Diop, N. Friese, X. Pascaud, J. Junien et al., Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral ??-opioid receptors, European Journal of Pharmacology, vol.324, issue.2-3, pp.2-3211, 1997.
DOI : 10.1016/S0014-2999(97)00089-7

G. Becker, D. Galandi, and H. Blum, Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review, J Pain Symptom Manage, 2007.

S. Ahmedzai, F. Nauck, G. Bar-sela, B. Bosse, P. Leyendecker et al., A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain, Palliative Medicine, vol.26, issue.1, pp.201250-60
DOI : 10.1177/0269216311418869

C. Yuan, J. Foss, O. Connor, M. Osinski, J. Roizen et al., Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study???, Pain, vol.83, issue.3, pp.631-636, 1999.
DOI : 10.1016/S0304-3959(99)00162-1

E. Mcnicol, D. Boyce, R. Schumann, and D. Carr, Mu-opioid antagonists for opioidinduced bowel dysfunction, Cochrane Database Syst Rev, issue.2, p.6332, 2008.

C. Yuan, J. Foss, O. Connor, M. Osinski, J. Karrison et al., Methylnaltrexone for Reversal of Constipation Due to Chronic Methadone Use, JAMA, vol.283, issue.3, pp.367-72, 2000.
DOI : 10.1001/jama.283.3.367

R. Portenoy, J. Thomas, M. Boatwright, M. Tran, D. Galasso et al., Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study, Journal of Pain and Symptom Management, vol.35, issue.5, pp.458-68, 2008.
DOI : 10.1016/j.jpainsymman.2007.12.005

N. Slatkin, R. Lynn, C. Su, W. Wang, and R. Israel, Characterization of Abdominal Pain During Methylnaltrexone Treatment of Opioid-Induced Constipation in Advanced Illness: A Post Hoc Analysis of Two Clinical Trials, Journal of Pain and Symptom Management, vol.42, issue.5, pp.754-60, 2011.
DOI : 10.1016/j.jpainsymman.2011.02.015

B. Randazzo, M. Duerden, S. Schulman, E. Tzanis, D. Yu et al., S1049 Characteristics of Gastrointestinal Adverse Events in Patients With Opioid-Induced Constipation and Chronic Non-Malignant Pain Treated With Subcutaneous Methylnaltrexone, Gastroenterology, vol.138, issue.5, pp.167-167, 2010.
DOI : 10.1016/S0016-5085(10)60765-2

J. Bernard, Données fondamentales (anatomie, physiologie) sur la sensibilité et la douleur viscérales. Douleur Analg, p.3, 1998.

C. Knowles and Q. Aziz, Basic and clinical aspects of gastrointestinal pain, Pain, vol.141, issue.3, 2009.
DOI : 10.1016/j.pain.2008.12.011

H. Sato, J. Droney, R. J. Olesen, A. Staahl, C. Andresen et al., Gender, Variation in Opioid Receptor Genes and Sensitivity to Experimental Pain, Molecular Pain, vol.32, issue.1, p.20, 2013.
DOI : 10.1093/bioinformatics/bth457

Y. Low, C. Clarke, and B. Huh, Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management, Singapore Med J, vol.53, issue.5, pp.357-60, 2012.

B. Lian, L. Vera-portocarrero, T. King, M. Ossipov, and F. Porreca, Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity, Brain Research, vol.1358, pp.64-70, 2010.
DOI : 10.1016/j.brainres.2010.08.032

H. Hassanian-moghaddam, S. Afzali, and A. Pooya, Withdrawal syndrome caused by naltrexone in opioid abusers, Human & Experimental Toxicology, vol.32, issue.9, 2013.
DOI : 10.1177/0960327112450901

E. Scarpellini, R. Vos, E. Deloose, A. Papathanasopoulos, A. Rotondo et al., P.1.180: INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN, Digestive and Liver Disease, vol.43, issue.5, pp.868-868, 2011.
DOI : 10.1016/S1590-8658(11)60408-8

E. Scarpellini, R. Vos, K. Blondeau, N. Rommel, and J. Tack, 420 Effect of Methylnaltrexone on Esophageal Function in Man, Gastroenterology, vol.142, issue.5, pp.93-93, 2012.
DOI : 10.1016/S0016-5085(12)60356-4

D. Murphy, J. Sutton, L. Prescott, and M. Murphy, Opioid-induced Delay in Gastric Emptying, Anesthesiology, vol.87, issue.4, pp.765-70, 1997.
DOI : 10.1097/00000542-199710000-00008

I. Moerman, P. Franck, and F. Camu, Evaluation of methylnaltrexone for the reduction of postoperative vomiting and nausea incidences, Acta Anaesthesiol Belg, vol.46, pp.3-4127, 1995.

P. Singleton, M. Lingen, M. Fekete, J. Garcia, and J. Moss, Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation, Microvascular Research, vol.72, issue.1-2, pp.3-11, 2006.
DOI : 10.1016/j.mvr.2006.04.004

A. Mackey, L. Green, P. Greene, and M. Avigan, Methylnaltrexone and Gastrointestinal Perforation, Journal of Pain and Symptom Management, vol.40, issue.1, pp.1-3, 2010.
DOI : 10.1016/j.jpainsymman.2010.01.011

T. Meier and . Relistor, S final assessment report on PSUR, Federal institute for drugs and medical devices, 2009.

A. European-medicines, EPAR -Procedural steps taken and scientific information after authorization Available from: URL: <http, Relistor, 2013.